Skip to main content
Top
Published in: Familial Cancer 2/2016

Open Access 01-04-2016 | Original Article

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety

Authors: Erica Sermijn, Liesbeth Delesie, Ellen Deschepper, Ingrid Pauwels, Maryse Bonduelle, Erik Teugels, Jacques De Grève

Published in: Familial Cancer | Issue 2/2016

Login to get access

Abstract

Background: Predictive genetic testing has high impact on cancer prevention for BRCA carriers and passing this information in BRCA families is important. Mostly, this is proband-mediated but this path is defective and denies relatives lifesaving information. Objective: To assess the efficacy/safety of an intervention, in which relatives are actively informed. Design: Sequential prospective study in new BRCA families. The proband informed relatives about predictive testing (phase I). After 6 months, a letter was sent to adult relatives who had not been reached (phase II). Then a phone call was made to obtain a final notion of their wishes. All subjects received psychometric testing (State-Trait Anxiety Inventory, STAI), an interview and routine counselling. Results: Twenty families were included. Twenty-four of the relatives could not be reached, 59 were ‘decliners’, 47 participated by the proband and 42 by the letter. Predictive testing was performed in 98 % of the participants of which 30 were mutation carriers. The intervention is psychologically safe: the 95 % CI for the estimated mean difference in STAI DY1 between phase II/I subjects (mean difference −1.07, 95 % CI −4.4 to 2.35, p = 0.53) shows that the mean STAI DY1 score (measured at first consult) for phase II is no more than 2.35 units higher than for phase I, which is not relevant. Conclusions: A protocol directly informing relatives nearly doubles the number of relatives tested and is psychologically safe. This should lead to a change in counselling guidelines in families with a strong germline predisposition for cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28CrossRefPubMed Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28CrossRefPubMed
2.
go back to reference Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral
4.
go back to reference Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822CrossRefPubMed Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822CrossRefPubMed
5.
go back to reference Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742CrossRefPubMed Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742CrossRefPubMed
6.
go back to reference Forrest L, Delatycki M, Curnow L, Skene L, Aitken M (2012) An audit of clinical service examining the uptake of genetic testing by at-risk family members. Genet Med 14(1):122–128CrossRefPubMed Forrest L, Delatycki M, Curnow L, Skene L, Aitken M (2012) An audit of clinical service examining the uptake of genetic testing by at-risk family members. Genet Med 14(1):122–128CrossRefPubMed
8.
go back to reference Vos J, Menko F, Jansen AM, van Asperen CJ, Stiggelbout AM, Tibben A (2011) A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer 10(1):87–96CrossRefPubMedPubMedCentral Vos J, Menko F, Jansen AM, van Asperen CJ, Stiggelbout AM, Tibben A (2011) A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer 10(1):87–96CrossRefPubMedPubMedCentral
9.
go back to reference Tangutoori S, Baldwin P, Sridhar S (2015) PARP inhibitors: a new era of targeted therapy. Maturitas 81(1):5–9CrossRefPubMed Tangutoori S, Baldwin P, Sridhar S (2015) PARP inhibitors: a new era of targeted therapy. Maturitas 81(1):5–9CrossRefPubMed
10.
go back to reference Spielberger C (1983) Manual for the state-trait anxiety inventory (form Y) self-evalution questionnaire. Consulting Psychologists Press, Palo Alto, CA Spielberger C (1983) Manual for the state-trait anxiety inventory (form Y) self-evalution questionnaire. Consulting Psychologists Press, Palo Alto, CA
11.
go back to reference Spielberger C, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA Spielberger C, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA
12.
go back to reference van der Ploeg H, Defares P, Spielberger C (1980) Handleiding bij de Zelf- Beoordelingsvragenlijst: Een Nederlandstalige Bewerking van de Spielberger State-Trait Anxiety Inventory (Manual of self-reported questionnaire. A Dutch translation of the Spielberger State-Trait Anxiety Inventory). Swets and Zeitlinger BV, Lisse van der Ploeg H, Defares P, Spielberger C (1980) Handleiding bij de Zelf- Beoordelingsvragenlijst: Een Nederlandstalige Bewerking van de Spielberger State-Trait Anxiety Inventory (Manual of self-reported questionnaire. A Dutch translation of the Spielberger State-Trait Anxiety Inventory). Swets and Zeitlinger BV, Lisse
13.
go back to reference Akta-Collan K, Haukkala A, Pylvänäinen K et al (2007) Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet 44:732–738CrossRef Akta-Collan K, Haukkala A, Pylvänäinen K et al (2007) Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet 44:732–738CrossRef
14.
go back to reference Evans D, Binchy A, Shenton A, Hopwood P, Craufurd D (2009) Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clin Genet 75:124–132CrossRefPubMed Evans D, Binchy A, Shenton A, Hopwood P, Craufurd D (2009) Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clin Genet 75:124–132CrossRefPubMed
16.
go back to reference Burke W, Press N (2006) Ethical obligations and counseling challenges in cancer genetics. J Natl Compr Cancer Netw 4(2):185–191 Burke W, Press N (2006) Ethical obligations and counseling challenges in cancer genetics. J Natl Compr Cancer Netw 4(2):185–191
18.
go back to reference Derks-Smeets IA, Gietel-Habets JJ, Tibben A et al (2014) Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Hum Reprod 29(5):1103–1112CrossRefPubMed Derks-Smeets IA, Gietel-Habets JJ, Tibben A et al (2014) Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Hum Reprod 29(5):1103–1112CrossRefPubMed
19.
go back to reference Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB et al (2007) Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14(12):3335–3344CrossRefPubMedPubMedCentral Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB et al (2007) Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14(12):3335–3344CrossRefPubMedPubMedCentral
20.
go back to reference Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med 345(3):159–164CrossRefPubMed Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med 345(3):159–164CrossRefPubMed
21.
go back to reference Menon U, Harper J, Sharma A et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577CrossRefPubMed Menon U, Harper J, Sharma A et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573–1577CrossRefPubMed
22.
go back to reference Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med 346(21):1616–1622CrossRefPubMed Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med 346(21):1616–1622CrossRefPubMed
23.
go back to reference Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19(15):3524–3531PubMed Warner E, Plewes DB, Shumak RS et al (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19(15):3524–3531PubMed
24.
go back to reference Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 116A(1):11–19CrossRefPubMed Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E (2003) Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 116A(1):11–19CrossRefPubMed
Metadata
Title
The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety
Authors
Erica Sermijn
Liesbeth Delesie
Ellen Deschepper
Ingrid Pauwels
Maryse Bonduelle
Erik Teugels
Jacques De Grève
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9854-4

Other articles of this Issue 2/2016

Familial Cancer 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine